Clinical Trial Technology Editorial

  1. Progress Made, But One-Third Of Results Still Missing
    2/24/2016 was created to inform the public of the results of clinical trials. Since the database went live in 2008, it has accumulated data on 200,000 trials in more than 170 countries. Compliance with established requirements is improving, but according to NIH data recently shared by Sen. Charles Grassley of Iowa, more than a third of applicable study results are still missing.

  2. Report: Pharma Is Most Resistant To Mobile Technology Use In Clinical Trials

    There are several technologies that promise to improve the ease and efficiency of conducting clinical trials in the future. The one that seems to hold the most potential for also easing the burden on patients, and helping sponsors with patient recruitment and retention, is mobile health technologies. But is the adoption rate of mHealth in clinical trials increasing?

  3. Clinical Outsourcing Market To See Continued Growth Through 2020

    A recent report from ISR, titled 2016 CRO Market Size Projections 2015-2020, paints an exciting and eventful future for the clinical trials market. This market has certainly been one of the best performing of late. In 2015, while the DJIA was down around 10 percent, clinical companies like PRA Health (up 78 percent), INC Research (up 64 percent) ICON (up 19 percent), Quintiles (up 6 percent), and PAREXEL (up 2 percent), all had great years.

  4. Biopharma Trends That Will Impact The Industry In 2016

    The beginning of the year is always a good time to take a look ahead at the trends most likely to impact the industry in the coming months. One area that is changing quickly, and which promises to impact clinical trials in the coming years, is biopharma. I recently spoke with Jim Esinhart, CEO of Chiltern, about some of these trends, including study protocols, big data, mergers, and new technologies.

  5. In Pharma Mobile Technology Makes Gains, Patient Enrollment Remains A Struggle

    A new report has been released by Insight Pharma Reports with some eye-opening results sure to get the attention of clinical executives. The Patient Enrollment & Recruitment Market Study performed a survey of 100 clinical trial professional staff members regarding their experiences with patient enrollment and recruitment.

  6. Using The Cost Of Adverse Events To Determine Drug Safety

    There are limitations to the drug approval system we currently have in place that is based on clinical trials. Data disclosures are often deemed inadequate, regulatory review and approval can be a lengthy process, and many would argue there is a bias in the industry and academia against publishing negative results.

  7. Using Real-World Data For Clinical Research: Challenges And Opportunities

    Across the country, there is growing awareness of challenges facing the clinical research enterprise. Among these challenges are the expense and logistical complexities of performing clinical trials, much of which is created by the need for elaborate, stand-alone data collection systems that are distinct from the systems used for normal clinical care.

  8. Mobile Devices In Clinical Trials: Tested, Effective, Proven!

    Patient recruitment and retention remains a challenge for most pharma companies. New mobile tools bring the promise of a better patient experience, which would serve to alleviate both problems. And yet the conservative nature of pharma, coupled with regulatory concerns, seem to be keeping these solutions from gaining adoption. It’s no surprise that some technology companies are attempting to prove the effectiveness of these mobile tools themselves.

  9. Julian Jenkins Joins Clinical Leader Editorial Advisory Board

    Dr. Julian Jenkins, VP and Head of Innovation, Performance and Technology within the Projects, Clinical Platforms & Sciences (PCPS) group in GSK Pharma R&D, has agreed to join the Editorial Advisory Board for Clinical Leader. Dr. Jenkins is accountable for performance management, business strategy and operations, and change management for PCPS, while maintaining a state of the art clinical and project technology infrastructure for the Pharma clinical organization.

  10. Quintiles Chairman Reflects On 33 Years In Drug Development

    On December 31, 2015 Dennis Gillings will officially step down as the Executive Chairman of Quintiles. When Gillings began working with pharma companies in 1974, shortly after coming to the U.S. from England, he was a professor of biostatistics at the University of North Carolina at Chapel Hill. His career in pharma started when he received a call from Hoechst, which later became Aventis and, subsequently, Sanofi